Why is Bristol Myers Squibb (BMY) stock down today?

Bristol Myers Squibb shares dropped 4.03%, falling from a previous close of $59.34 to $56.95, touching an intraday low of $56.78, on a day when the S&P 500 rose 0.38% and the Nasdaq (QQQ) gained 1.12%. The disconnect — a meaningful decline while the broader market advanced — points to a sector-specific headwind rather than a general market selloff.

The dominant identified pressure on Bristol Myers Squibb and large pharmaceutical peers today was the ongoing reshaping of drug pricing under the Trump administration. A Motley Fool report published this morning explicitly named Bristol Myers Squibb alongside Pfizer and AbbVie as companies whose outlooks are being reshaped by these pricing deals. When government-negotiated or mandated drug prices are lowered, it directly compresses the revenue and profit margins pharma companies can earn on their branded drugs — a mechanism that causes investors to reprice shares downward.

On the positive side, there was incremental pipeline news. Agilent received FDA approval for its PD-L1 companion diagnostic test, which identifies patients eligible for Bristol Myers' cancer drugs Opdivo and Opdivo Qvantig in several gastrointestinal cancers including esophageal and gastric cancers. Separately, a Zacks analysis highlighted advancements in Bristol Myers' CELMoD (Cereblon E3 Ligase Modulator) oncology program, and the FDA previously accepted the company's new drug application for mezigdomide in relapsed multiple myeloma, with a PDUFA decision date set for May 13, 2027. These pipeline developments, however, were not enough to offset the pricing-pressure concerns on the day.

Bristol Myers Squibb reports its next quarterly earnings on July 30, 2026. Its most recent quarter showed earnings per share of $1.58 against an estimate of $1.42, and revenue of $11.49 billion. The stock's forward price-to-earnings ratio of 9.2 — well below the trailing ratio of 16.0 — reflects the market's uncertainty about future earnings power, particularly in a drug-pricing policy environment that remains in flux.